Touchlight’s enzymatic doggybone DNA used in manufacture of Versameb’s VMB-100
A UK-based CDMO has landed a supply agreement with Versameb to provide its doggybone DNA for the company’s pipeline, including for its lead candidate to treat stress urinary incontinence.
Touchlight, a biotechnology company pioneering enzymatic DNA production, has signed a development and manufacturing pipeline agreement with Versameb AG, a pre-clinical stage company focused on discovering and developing RNA -based therapeutics.